


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):



wherein R⁷ and R²¹ are the same or are different and represent

-O-benzoyl,

[[OH,]] or


RC(=Y)-O-, wherein Y represents an oxygen atom, and R represents

piperazinyl 4-alkyl-piperazin-1-yl, alkyl, -O-phenyl, -N-alkyl -N,N-dialkyl or -

NH-phenyl, or

a pharmacologically acceptable salt thereof.

2. (Currently Amended) [[The]] A compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a} are the same or are different and represent

$R^aC(=Y^a)-O-$, wherein Y^a represents an oxygen atom, and R^a represents

a C_1 to C_{22} alkyl group,

an unsaturated C_2 to C_{22} alkyl group,

a C_3 to C_{14} cycloalkyl group

or a pharmacologically acceptable salt thereof.

3-18. (Canceled).

19. (Previously Presented) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-21-(N,N-dimethylcarbamoyloxy)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide, and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricos-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof.

20. (Canceled).

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Canceled).